Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2026 Feb 10;16:1798367. doi: 10.3389/fonc.2026.1798367

Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer

Frontiers Editorial Office*
PMCID: PMC12930266  PMID: 41743960

Following publication, significant concerns were raised regarding the integrity of the patient data and reporting within the manuscript. An investigation was conducted in accordance with Frontiers’ policies, and it was determined that the conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

Footnotes

Approved by: Sharon R. Pine, University of Colorado Anschutz Medical Campus, United States


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES